Eli Lilly and Company (NYSE:LLY) Shares Purchased by Motley Fool Asset Management LLC

Key Points

• Motley Fool Asset Management LLC increased its stake in Eli Lilly by 16.5%, holding 45,878 shares worth approximately $37.89 million, making it the fund's 10th largest position.
• Eli Lilly reported a net margin of 25.91% and a quarterly revenue of $15.56 billion, exceeding expectations and showcasing a 37.6% year-over-year revenue increase.
• The company announced a quarterly dividend of $1.50 per share, providing a 1.0% yield with a payout ratio of 48.82% as of the latest financial disclosures.

Motley Fool Asset Management LLC increased its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 16.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 45,878 shares of the company's stock after buying an additional 6,503 shares during the quarter. Eli Lilly and Company accounts for about 2.1% of Motley Fool Asset Management LLC's investment portfolio, making the stock its 10th largest position. Motley Fool Asset Management LLC's holdings in Eli Lilly and Company were worth $37,891,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in LLY. Garner Asset Management Corp raised its position in Eli Lilly and Company by 2.3% during the 4th quarter. Garner Asset Management Corp now owns 532 shares of the company's stock worth $411,000 after purchasing an additional 12 shares during the last quarter. Tobias Financial Advisors Inc. grew its holdings in Eli Lilly and Company by 4.1% during the 4th quarter. Tobias Financial Advisors Inc. now owns 307 shares of the company's stock worth $237,000 after acquiring an additional 12 shares during the period. Redwood Investments LLC grew its holdings in Eli Lilly and Company by 0.5% during the 4th quarter. Redwood Investments LLC now owns 2,209 shares of the company's stock worth $1,705,000 after acquiring an additional 12 shares during the period. Hobbs Wealth Management LLC grew its holdings in Eli Lilly and Company by 0.8% during the 1st quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company's stock worth $1,205,000 after acquiring an additional 12 shares during the period. Finally, Hixon Zuercher LLC grew its holdings in Eli Lilly and Company by 0.7% during the 1st quarter. Hixon Zuercher LLC now owns 1,789 shares of the company's stock worth $1,477,000 after acquiring an additional 12 shares during the period. Hedge funds and other institutional investors own 82.53% of the company's stock.

Wall Street Analysts Forecast Growth

LLY has been the subject of several research reports. Morgan Stanley restated an "overweight" rating and issued a $1,135.00 target price (up from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. Erste Group Bank downgraded Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. Leerink Partnrs downgraded Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 7th. Leerink Partners reiterated a "market perform" rating and set a $715.00 price target on shares of Eli Lilly and Company in a research note on Thursday, August 7th. Finally, Deutsche Bank Aktiengesellschaft cut their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a research note on Monday. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and sixteen have given a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $964.88.

Insiders Place Their Bets

In other news, Director Gabrielle Sulzberger bought 117 shares of the firm's stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the purchase, the director owned 2,703 shares of the company's stock, valued at $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director J Erik Fyrwald acquired 1,565 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the acquisition, the director owned 74,578 shares of the company's stock, valued at $47,903,686.74. The trade was a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Trading Up 3.5%

Shares of LLY stock traded up $22.96 on Thursday, hitting $683.45. 5,986,752 shares of the stock traded hands, compared to its average volume of 4,120,288. The firm's 50-day moving average price is $767.52 and its two-hundred day moving average price is $796.25. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The stock has a market capitalization of $646.86 billion, a PE ratio of 44.68, a PEG ratio of 0.90 and a beta of 0.44. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. The firm had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%. Eli Lilly and Company's revenue was up 37.6% compared to the same quarter last year. During the same period last year, the business posted $3.92 earnings per share. As a group, analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be given a $1.50 dividend. The ex-dividend date is Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.9%. Eli Lilly and Company's payout ratio is currently 39.22%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.